H Yasuda1, M Yamaya, M Yanai, T Ohrui, H Sasaki. 1. Department of Geriatric and Respiratory Medicine, Tohoku University School of Medicine, Sendai 980-8574, Japan. yasuda@geriat.med.tohoku.ac.jp
Abstract
BACKGROUND: Exhaled carbon monoxide has been reported to increase in inflammatory pulmonary diseases and to be correlated with blood carboxyhaemoglobin (Hb-CO) concentration. A study was undertaken to determine whether arterial blood Hb-CO increases in patients with inflammatory pulmonary diseases. METHODS: The Hb-CO concentration in arterial blood was measured with a spectrophotometer in 34 normal control subjects, 24 patients with bronchial asthma, 52 patients with pneumonia, and 21 patients with idiopathic pulmonary fibrosis (IPF). RESULTS: The mean (SE) Hb-CO concentrations in patients with bronchial asthma during exacerbations (n=24, 1.05 (0.05)%), with pneumonia at the onset of illness (n=52, 1.08 (0.06)%), and with IPF (n=21, 1.03 (0.09)%) were significantly higher than those in control subjects (n=34, 0.60 (0.07)%) (mean difference 0.45% (95% confidence interval (CI) 0.23 to 0.67), p<0.01 in patients with bronchial asthma, mean difference 0.48% (95% CI 0.35 to 0.60), p<0.0001 in patients with pneumonia, and mean difference 0.43% (95% CI 0.26 to 0.61) p<0.001 in patients with IPF). In 20 patients with bronchial asthma the Hb-CO concentration decreased after 3 weeks of treatment with oral glucocorticoids (p<0.001). In 20 patients with pneumonia the Hb-CO concentration had decreased after 3 weeks when patients showed evidence of clinical improvement (p<0.001). The values of C-reactive protein (CRP), an acute phase protein, correlated with Hb-CO concentrations in patients with pneumonia (r=0.74, p<0.0001) and in those with IPF (r=0.46, p<0.01). In patients with bronchial asthma changes in Hb-CO concentrations were significantly correlated with those in forced expiratory volume in 1 second (FEV(1)) after 3 weeks (r=0.67, p<0.01). Exhaled carbon monoxide (CO) concentrations were correlated with Hb-CO concentrations (n=33, r=0.80, p<0.0001). CONCLUSIONS: Hb-CO concentrations are increased in inflammatory pulmonary diseases including bronchial asthma, pneumonia, and IPF. Measurement of arterial Hb-CO may be a useful means of monitoring pulmonary inflammation.
BACKGROUND: Exhaled carbon monoxide has been reported to increase in inflammatory pulmonary diseases and to be correlated with blood carboxyhaemoglobin (Hb-CO) concentration. A study was undertaken to determine whether arterial blood Hb-CO increases in patients with inflammatory pulmonary diseases. METHODS: The Hb-CO concentration in arterial blood was measured with a spectrophotometer in 34 normal control subjects, 24 patients with bronchial asthma, 52 patients with pneumonia, and 21 patients with idiopathic pulmonary fibrosis (IPF). RESULTS: The mean (SE) Hb-CO concentrations in patients with bronchial asthma during exacerbations (n=24, 1.05 (0.05)%), with pneumonia at the onset of illness (n=52, 1.08 (0.06)%), and with IPF (n=21, 1.03 (0.09)%) were significantly higher than those in control subjects (n=34, 0.60 (0.07)%) (mean difference 0.45% (95% confidence interval (CI) 0.23 to 0.67), p<0.01 in patients with bronchial asthma, mean difference 0.48% (95% CI 0.35 to 0.60), p<0.0001 in patients with pneumonia, and mean difference 0.43% (95% CI 0.26 to 0.61) p<0.001 in patients with IPF). In 20 patients with bronchial asthma the Hb-CO concentration decreased after 3 weeks of treatment with oral glucocorticoids (p<0.001). In 20 patients with pneumonia the Hb-CO concentration had decreased after 3 weeks when patients showed evidence of clinical improvement (p<0.001). The values of C-reactive protein (CRP), an acute phase protein, correlated with Hb-CO concentrations in patients with pneumonia (r=0.74, p<0.0001) and in those with IPF (r=0.46, p<0.01). In patients with bronchial asthma changes in Hb-CO concentrations were significantly correlated with those in forced expiratory volume in 1 second (FEV(1)) after 3 weeks (r=0.67, p<0.01). Exhaled carbon monoxide (CO) concentrations were correlated with Hb-CO concentrations (n=33, r=0.80, p<0.0001). CONCLUSIONS: Hb-CO concentrations are increased in inflammatory pulmonary diseases including bronchial asthma, pneumonia, and IPF. Measurement of arterial Hb-CO may be a useful means of monitoring pulmonary inflammation.
Authors: M Monma; M Yamaya; K Sekizawa; K Ikeda; N Suzuki; T Kikuchi; T Takasaka; H Sasaki Journal: Clin Exp Allergy Date: 1999-11 Impact factor: 5.018
Authors: Kazuhisa Konishi; Kevin F Gibson; Kathleen O Lindell; Thomas J Richards; Yingze Zhang; Rajiv Dhir; Michelle Bisceglia; Sebastien Gilbert; Samuel A Yousem; Jin Woo Song; Dong Soon Kim; Naftali Kaminski Journal: Am J Respir Crit Care Med Date: 2009-04-10 Impact factor: 21.405
Authors: Robert Naples; Dan Laskowski; Kevin McCarthy; Emmea Mattox; Suzy A A Comhair; Serpil C Erzurum Journal: Lung Date: 2015-02-14 Impact factor: 2.584
Authors: H Yasuda; S Okinaga; M Yamaya; T Ohrui; M Higuchi; M Shinkawa; S Itabashi; K Nakayama; M Asada; A Kikuchi; S Shibahara; H Sasaki Journal: J Med Genet Date: 2006-04 Impact factor: 6.318
Authors: Stanley J Szefler; James F Chmiel; Anne M Fitzpatrick; George Giacoia; Thomas P Green; Daniel J Jackson; Heber C Nielsen; Wanda Phipatanakul; Hengameh H Raissy Journal: J Allergy Clin Immunol Date: 2013-11-28 Impact factor: 10.793
Authors: Samar Farha; Kewal Asosingh; Daniel Laskowski; Jeffrey Hammel; Raed A Dweik; Herbert P Wiedemann; Serpil C Erzurum Journal: Am J Respir Crit Care Med Date: 2009-06-11 Impact factor: 21.405
Authors: Bertha Estrella; Ramiro Estrella; Jorge Oviedo; Ximena Narváez; María T Reyes; Miguel Gutiérrez; Elena N Naumova Journal: Environ Health Perspect Date: 2005-05 Impact factor: 9.031